Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

The registered record

Accession number

NCT05888922

Lead sponsor

Industrial Farmacéutica Cantabria, S.A. (industry)

Collaborators

Bioskin GmbH, Astrum CRO, S.L.

Registered conditions naming hair loss

Androgenetic AlopeciaFemale Pattern Baldness

Official title

International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia

Interventions

• DrugMinoxidil Tablets
• DrugMinoxidil Topical
• DrugPlacebo oral tablet
• DrugVehicle solution

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type

interventional

Phase

Phase 3

Allocation

randomized

Masking

quadruple

Primary purpose

treatment

Enrolment

520 participants (estimated)

Sites

13 locations in Germany

What it measures

1. Change in Target Area non vellus Hair Counts (TAHC)

   Time frame: From baseline to week 24

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex

female

Age

18 Years

Healthy volunteers

not accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start

17 October 2024 (actual)

Primary completion

October 2026 (estimated)

Study completion

November 2026 (estimated)

First posted

5 June 2023 (actual)

Last update posted

12 May 2026 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: a primary completion registered as 2026-10 is a month, and rendering it as 1 October 2026 would invent a day the sponsor did not register.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Androgenetic Alopecia: Complete GuideNew Hair Loss Treatments in Clinical Trials: Clascoterone, Pyrilutamide and What the Published Data Actually ShowComplete Guide to Finasteride for Hair LossMinoxidil 5% Complete Guide: How to Apply for Best ResultsFemale Pattern Hair Loss: Treatment Options That WorkWomen's Hair Loss: The Complete GuideSpironolactone for Hair Loss in WomenDiffuse Thinning vs. Pattern Baldness: How to Tell the Difference (2026 Guide)How to Tell If You're Going Bald: Early Signs & Self-Assessment Guide (2026)

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT05888922 on ClinicalTrials.gov · All 157 trials in the pipeline